Jeil Pharmaceutical Launches Diabetes Combination Drug 'Duglow Tablet'..."Will Become a New Treatment Option"

Dapagliflozin-Pioglitazone Combination

Jeil Pharmaceutical announced on the 4th that it has launched a new diabetes combination product called 'Duglow Tablet (active ingredients dapagliflozin and pioglitazone)'.

Duglow Tablet is a combination drug that combines dapagliflozin, a sodium-glucose co-transporter (SGLT)-2 inhibitor, and pioglitazone, a thiazolidinedione (TZD) class ingredient. Both ingredients were classified as high-efficacy agents in the 2023 American Diabetes Association (ADA) guidelines. It is explained that it shows high effectiveness in lowering blood sugar and is useful for blood sugar management in patients with type 2 diabetes.

Dapagliflozin works by excreting sugar through urine, while pioglitazone improves insulin resistance, making it effective for long-term blood sugar control.

Furthermore, the combination of the two ingredients compensates for each other's shortcomings and works complementarily. Jeil Pharmaceutical explained that concerns about side effects such as weight changes or edema are reduced, and it is expected to prevent major complications in type 2 diabetes patients, such as stroke, myocardial infarction, cardiovascular disease, and non-alcoholic fatty liver disease.

Jeil Pharmaceutical stated that according to its own phase 3 clinical trial results, the group receiving metformin and Duglow Tablet showed an additional 0.69% reduction in glycated hemoglobin when switching from metformin and dapagliflozin to metformin and Duglow Tablet, with no significant difference in adverse reactions. They also confirmed significant improvements in lipid levels such as homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) compared to the control group.

Yang Ji-hyo, Marketing PM at Jeil Pharmaceutical, said, "In a situation where active blood sugar management is emphasized to prevent complications, the ultimate goal of diabetes treatment, Duglow Tablet will be a new treatment option for diabetes patients," adding, "We hope that Duglow Tablet will help improve patients' quality of life through effective blood sugar control and prevention of cardiovascular and cerebrovascular diseases."